Skip to main content

Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report

A Correction to this article was published on 05 May 2023

This article has been updated

Abstract

Background

Rhabdomyolysis is a potentially life-threatening disease caused by melting or necrosis of skeletal muscle cells and leakage of muscle components into the bloodstream. It has been reported that the interaction of the HMG-CoA reductase inhibitor rosuvastatin with the renal anemia drug vadadustat increases the blood concentration of rosuvastatin in vitro. In this study, we report a case of suspected rhabdomyolysis caused by the drug interaction of rosuvastatin and vadadustat in clinical practice.

Case presentation

A 62-year-old male with medical records of hypertension, myocardial infarction, chronic renal failure, renal anemia, dyslipidemia, and alcoholic liver disease. The patient had been diagnosed with chronic kidney disease (CKD) at the Department of Nephrology, and treated by outpatient care with renal support therapy for the past two years. On X-63 day, his prescription was rosuvastatin (10 mg/day) and a continuous erythrocyte-stimulating agent, epoetin beta pegol (genetical recombination, 100 μg). X-Day 0, blood tests revealed creatine phosphokinase (CPK) 298 U/L, serum creatinine (SCr) 5.26 mg/dL, and hemoglobin (Hb) 9.5 g/dL; thus, the prescription was changed from epoetin beta pegol 100 μg to vadadustat 300 mg/day. On X + day 80, a prescription for a diuretic (azosemide 15 mg/day) was added for swelling of the lower extremities. On X + day 105, we found CPK 16,509 U/L, SCr 6.51 mg/dL, and Hb 9.5 g/dL. The patient was diagnosed as rhabdomyolysis and hospitalized. After hospitalization, rosuvastatin and vadadustat were discontinued and we administered intravenous fluids. Thereafter, CPK and SCr values of the patient improved. On X + day 122, CPK improved to 29 U/L, SCr to 2.6 mg/dL, and Hb to 9.6 g/dL, and he was discharged on X + day 124. At discharge, rosuvastatin 2.5 mg/day was resumed. A blood test on X + day 133 showed CPK 144 U/L and SCr 4.2 mg/dL.

Conclusion

We experienced a case of rhabdomyolysis caused by drug interactions between rosuvastatin and vadadustat.

Introduction

Rhabdomyolysis is a potentially fatal disease caused by melting or necrosis of skeletal muscle cells and the leakage of muscle components into the bloodstream.

Previous studies reported that the drug interaction of rosuvastatin [1], an HMG-CoA reductase inhibitor, and vadadustat [2, 3], a therapeutic drug for Hypoxia Inducible Factor Prolyl Hydroxylase renal anemia, increases the blood concentration of rosuvastatin in vitro [4, 5]. In this study, we report a case of rhabdomyolysis [6] caused by the drug-interaction of rosuvastatin and vadadastat in clinical practice.

Case presentation

A 62-year-old male with medical records of hypertension, myocardial infarction, chronic renal failure, renal anemia, dyslipidemia, and alcoholic liver disease. The patient had been diagnosed with CKD at the Department of Nephrology, and treated by outpatient care with renal support therapy for the past two years. On X-63 day, his prescription was rosuvastatin (10 mg/day) and a continuous erythrocyte-stimulating agent, epoetin beta pegol [7] (genetical recombination, 100 μg). Blood tests revealed SCr 3.75 mg/dL, Hb 9.5 g/dL, high density lipoprotein cholesterol (HDL-c) 69 mg/dL, and low density lipoprotein cholesterol (LDL-c) 21 mg/dL. X-day 0, blood tests revealed CPK 298 U/L, SCr 5.26 mg/dL, Hb 9.5 g/dL, HDL-c 62 mg/dL, and LDL-c 16 mg/dL, so the prescription was changed from epoetin beta pegol 100 μg to vadadustat 300 mg/day. On X + day 80, a prescription for a diuretic (azosemide [8] 15 mg/day) was added for swelling of the lower extremities. Muscle pain in both legs appeared on around X + 80 day. Furthermore, at the time of admission, the patient had persistent muscle pain in both legs, further muscle weakness, and increase of CPK level. Reddish-brown urine, possibly myoglobinuria, was also observed. Therefor the patient was diagnosis as rhabdomyolysis.

On X + day 105 at his regular clinic visit, blood tests showed CPK 16,509 U/L, SCr 6.51 mg/dL, Hb 9.5 g/dL, HDL-c 33 mg/dL, and LDL-c 16 mg/dL. The patient was diagnosed with rhabdomyolysis and hospitalized. On admission, the pharmacist suggested to the doctor that the discontinuation of vadadustat and rosuvastatin to the physician as a possible cause of the elevated CPK levels due to drug interactions. As a result, both drugs were discontinued and the patient was administered intravenous fluids. Thereafter, CPK and SCr values improved. The pharmacist suggested to the doctor epoetin beta pegol, which had been previously administered for renal anemia, since the CPK level had decreased. Furthermore, the doctor asked the pharmacist to resume rosuvastatin because of ischemic heart disease. The pharmacist informed the doctor that statins alone have few side effects such as rhabdomyolysis [9], and the drug was resumed in small doses in consideration of safety.

On X + day 122, CPK improved to 29 U/L, SCr 2.6 mg/dL, and Hb 9.6 g/dL, and he was discharged on X + day 124. At discharge, rosuvastatin 2.5 mg/day was resumed. A blood test on X + day 133 showed CPK 144 U/L SCr 4.22 mg/dL, Hb 8.9 g/dL, HDL-c 57 mg/dL, and LDL-c 64 mg/dL (Fig. 1).

Fig. 1
figure 1

Clinical course

Discussion and conclusion

Rhabdomyolysis is a potentially life-threatening condition caused by the melting and necrosis of skeletal muscle cells and the leakage of muscle components into the blood [6].

The diagnostic criteria for rhabdomyolysis refer to a CPK level of at least five times the reference value, and symptoms include myalgia and myoglobinuria. Treatment includes discontinuation of the causative drugs, if any, and application of infusion fluids [10]. Congenital rhabdomyolysis and acquired rhabdomyolysis are known to be causes of rhabdomyolysis. Acquired rhabdomyolysis has been reported to be caused by excessive exercise [11], alcohol [12], liver and kidney damage [13, 14] and especially HMG-CoA reductase inhibition (statins) [15]. Statin-induced rhabdomyolysis has been reported to occur in interactions with drugs such as fibrates and cyclosporine [16], although few cases have been reported alone. In addition, rhabdomyolysis has been reported to have occurred because of increased blood levels of statins due to drug interactions [17]. It has been reported that in vitro a combination of rosuvastatin and vadadustat increased the plasma concentration of rosuvastatin [4, 5] a substrate of breast cancer resistance protein (BCRP) [18], due to the inhibitory effect of vadadustat on BCRP.

In this study, we experienced a case of rhabdomyolysis that was thought to be caused by the interaction between the statin rosuvastatin and the renal anemia drug vadadustat. Since statins have evidence for secondary prevention of ischemic heart disease, rosuvastatin was taken by this patient aiming for LDL-c < 70 mg/dL [19]. And it was thought that the plasma concentration of rosuvastatin was increased by vadadustat, which led to an increase in CKP and rhabdomyolysis. Furthermore, hepatic and renal impairment, alcohol intake, excessive exercise, and dehydration due to diuretics may have contributed to rhabdomyolysis. In addition, after resuming only rosuvastatin at the time of discharge, CPK and SCr did not increase, suggesting that rhabdomyolysis was caused by the combination of rosuvastatin and vadadustat. Judging from this case, it would be advisable to administer rosuvastatin carefully when it is combined with vadadustat, taking into account drug interactions and patient background.

Vadadustat taken alone has been reported to have no effect on cholesterol levels [20]. When vadadustat and rosuvastatin were co-administered, LDL-c did not change, but HDL-c decreased. Therefore, the combination of rosuvastatin and vadadustat may influence cholesterol levels. Though the cause was not identified in this study. Further verification is necessary in the future.

In conclusion, the pharmacist was aware from the package insert of vadadustat and rosuvastatin as stating “concomitant use is cautioned because the Cmax and AUC of rosuvastatin may increase with concomitant use” [4], in other words, it causes the drug interaction between them resulting in an increase in the Cmax and AUC of rosuvastatin. This predicted an increase in CPK and may have caused rhabdomyolysis from persistent myalgia and myoglobinuria. This was indicated to the doctor.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Change history

References

  1. Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002;20:303–28. https://doi.org/10.1111/J.1527-3466.2002.TB00099.X.

    Article  CAS  PubMed  Google Scholar 

  2. Locatelli F, Fishbane S, Block GA, MacDougall IC. targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol. 2017;45:187–99. https://doi.org/10.1159/000455166.

    Article  CAS  PubMed  Google Scholar 

  3. Nangaku M, Kondo K, Kokado Y, et al. Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. J Am Soc Nephrol. 2021;32:1779–90. https://doi.org/10.1681/ASN.2020091311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health L and W. Report on the Deliberation Results Vadadustat. https://www.pmda.go.jp/files/000243933.pdf. Accessed 25-9-2022

  5. Hashimoto Y, Michiba K, Maeda K, Kusuhara H. Quantitative prediction of pharmacokinetic properties of drugs in humans: Recent advance in vitro models to predict the impact of efflux transporters in the small intestine and blood-brain barrier. J Pharmacol Sci. 2022;148:142–51. https://doi.org/10.1016/J.JPHS.2021.10.010.

    Article  CAS  PubMed  Google Scholar 

  6. Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am Fam Physician. 2002;65:907–913. https://www.aafp.org/pubs/afp/issues/2002/0301/p907.html. Accessed 9 Oct, 2022.

  7. Nangaku M, Hamano T, Akizawa T, et al. Daprodustat compared with Epoetin beta Pegol for anemia in Japanese patients not on dialysis: a 52-Week Randomized Open-Label Phase 3 Trial. Transl Res Res Artic Am J Nephrol. 2021;52:26–35. https://doi.org/10.1159/000513103.

    Article  CAS  Google Scholar 

  8. Tsutsui T, Tsutamoto T, Maeda K, Kinoshita M. Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure. J Cardiovasc Pharmacol. 2001;38(SUPPL. 1):81–6. https://doi.org/10.1097/00005344-200110001-00017.

    Article  Google Scholar 

  9. Paul M Ridker, M.D., Eleanor Danielson, M.I.A., Francisco A.H. Fonseca, M.D., Jacques Genest, M.D., Antonio M. Gotto, Jr., M.D., John J.P. Kastelein, M.D., Wolfgang Koenig, M.D., Peter Libby, M.D., Alberto J. Lorenzatti, M.D., Jean G. MacFadyen, B.A., Børge G. Nordestgaard, M.D., James Shepherd, M.D., et al., for the JUPITER Study Group.Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive. N Engl J Med 2008; 359:2195–2207. https://doi.org/10.1056/NEJMoa0807646

  10. Luis O. Chavez, Monica Leon, Sharon Einav & Joseph Varon. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Critical Care volume 20, Article number: 2016;135. https://doi.org/10.1186/s13054-016-1314-5

  11. Line RL, Rust GS. Acute exertional rhabdomyolysis. Am Fam Physician. 1995;52:502–6. https://doi.org/10.2519/jospt.2013.0420.

    Article  CAS  PubMed  Google Scholar 

  12. O Bessa Jr. Alcoholic rhabdomyolysis. Conn Med. 1995;59:519–521. https://pubmed.ncbi.nlm.nih.gov/7587180/. Accessed 12 Oct, 2022.

  13. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781–90. https://doi.org/10.1016/S0140-6736(07)60716-8.

    Article  CAS  PubMed  Google Scholar 

  14. Ronaldson KJ, O’Shea JM, Boyd IW. Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin. Drug Saf. 2006;29:1061–7. https://doi.org/10.2165/00002018-200629110-00005.

    Article  CAS  PubMed  Google Scholar 

  15. Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: A review. Muscle Nerve. 2002;25:332–47. https://doi.org/10.1002/MUS.10053.

    Article  CAS  PubMed  Google Scholar 

  16. Alejandro DSJ, Petersen J. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine. J Am Soc Nephrol. 1994;5:153–60. https://doi.org/10.1681/ASN.V52153.

    Article  CAS  PubMed  Google Scholar 

  17. Hougaard Christensen MM, Bruun Haastrup M, Øhlenschlaeger T, Esbech P, Arnspang Pedersen S, Bach Dunvald AC, Bjerregaard Stage T, et al. Interaction potential between clarithromycin and individual statins-a systematic review. Basic Clin Pharmacol Toxicol. 2020;126:307–17.

    Article  CAS  PubMed  Google Scholar 

  18. Mao Q, Unadkat JD. Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update. AAPS J. 2015;17:65. https://doi.org/10.1208/S12248-014-9668-6.

    Article  CAS  PubMed  Google Scholar 

  19. Rosenson RS, Hayward RA, Lopez-Sendon J. Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease. UpToDate, 2022. Accessed 28 Feb 2023.

  20. Sanghani NS, M.D., Volker H. Haase, M.D. HIF-prolyl hydroxylase inhibitors in renal anemia:current clinical experience. Adv Chronic Kidney Dis. 2019;26:253–66. https://doi.org/10.1053/j.ackd.2019.04.004.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the staff of the Pharmacy Department of Aso Medical Center for their cooperation.

Funding

This research was not funded by specific grants from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Contributions

K.S., S.H., and Y.I. were involved in obtaining ethical approval and in the conception and design of the study. S.H., M.H., and Y.H. were involved in data acquisition. K.S. analyzed the data. S.Y., and Y.K. supervised the study. K.S. wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Keiki Sakurama.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the ethics committee of Aso Medical Center ( Numbers: 2022–No.1). Written informed consent was obtained from the patient.

Consent for publication

Consent for publication was obtained from the patient.

Competing interests

All other authors declare no conflict of interest. Each author has confirmed compliance with the journal's requirements for authorship.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article has been updated to correct the title.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sakurama, K., Iguchi, Y., Haruki, S. et al. Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report. J Pharm Health Care Sci 9, 13 (2023). https://doi.org/10.1186/s40780-023-00281-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40780-023-00281-2

Keywords